Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol’s Focus Returns To IO Following Celgene Vote

Apr 23 2019

• By Joseph Haas

Business Balance - A businessman carrying paperwork walking over a tight rope.

Related Content

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity

Oct 25 2018

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Jan 04 2019

Celgene Gives Reassurances That Key Products And Programs Remain On Track

Feb 01 2019

Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

Feb 02 2019

As Expected: Shareholders Back Bristol's $74bn Celgene Buy

Apr 12 2019

Keytruda NSCLC Approval Will Test PD-L1 Expression

Oct 02 2015

Related Companies

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Merck & Co., Inc.

Pfizer Inc.

Merck KGaA

Additional Topics

Sales & Earnings Business Strategies Commercial ImmunoOncology Companies Cancer BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window